News Express, will bedaquiline still free in 2024?

Bedaquiline (Bedaquiline) is a new compound that belongs to the class of diarylquinolines used to treat multidrug-resistant tuberculosis; cure and culture conversion rates with bedaquiline are promising. A cost-effectiveness analysis shows that adding bedaquiline to background multidrug-resistant tuberculosis regimens will improve health outcomes and reduce costs in high-TB burden countries. Bedaquiline in 2024is not necessarily a free drug.

Bedaquiline received accelerated approval in the United States in 2012 for the treatment of pulmonary MDR-TB as part of appropriate combination therapy in adult patients who are resistant or intolerant to other treatment options. However, in 2013, there were limited data and a high mortality rate in patients receiving bedaquiline in phase II randomized controlled trials, appropriate patient inclusion, signed informed consent, compliance with WHO recommended MDR-TB protocol design principles, close monitoring, and active pharmacovigilance. Since 2013, many countries have included bedaquiline as part of their MDR-TB management strategies, and in 2018, WHO updated guidelines for the use of bedaquiline in MDR-TB, including in children over 6 years of age.

The drug is sold in China under the name of daquiline fumarate tablets and has been included in the scope of medical insurance. The price of a common specification of 100mg*24 tablets per box may be around 10,000 yuan, which is relatively expensive. The price of the Russian version of Bedaquiline sold overseas, Specifications100mg*188 tablets per box, may be around RMB 15,000 (the price may fluctuate due to the exchange rate). The pharmaceutical ingredients of Bedaquiline sold domestically and abroad are basically the same. Currently, there are no generic bedaquiline drugs produced and marketed overseas. For specific prices and drug information of overseas drugs, please consult Yaode Medical Consultant.